Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data

Zacks2024-11-15

As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory updates. Novavax NVAX was in focus this week as investors were ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2483331111?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6","is_english":true,"pubTime":"2024-11-15 03:16","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2483331111","market":"us","top_or_hot":-1,"title":"Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data","media":"Zacks","content":"<div>\n<p>As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory updates. Novavax NVAX was in focus this week as investors were ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biotech-stock-roundup-nvax-q3-191600128.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-15 03:16 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/biotech-stock-roundup-nvax-q3-191600128.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory updates. Novavax NVAX was in focus this week as investors were ...</p>\n\n<a href=\"https://finance.yahoo.com/news/biotech-stock-roundup-nvax-q3-191600128.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4505","symbol_name":"高瓴资本持仓","start_time":0,"source_url":"https://finance.yahoo.com/news/biotech-stock-roundup-nvax-q3-191600128.html","article_id":"2483331111","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/vtsVt8PEmb10KQ4cnwEJfQ--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2483331111","pubTimestamp":1731611760,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory updates. Novavax NVAX was in focus this week as investors were disappointed with the lowered guidance.Novavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per share.Revenues in the quarter amounted to $85 million, which beat the Zacks Consensus Estimate of $57 million. However, the top line declined 55% on a year-over-year basis.Novavax also announced that the FDA has lifted the clinical hold on its two pipeline programs, COVID-19-Influenza Combination  and stand-alone influenza vaccine candidates. The agency had initially placed this hold after a study participant who took the CIC shot as part of a phase II study reported nerve damage. With this hold removed, management is working with study investigators and other partner","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4505":"高瓴资本持仓","NVAX":"诺瓦瓦克斯医药","BK4588":"碎股","SNDX":"Syndax Pharmaceuticals, Inc. ","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","RNA":"Avidity Biosciences, Inc.","CR":"crane","BK4161":"工业机械","BK4547":"WSB热门概念","BK4139":"生物科技"},"translate_title":"生物科技股综述：NVAX第三季度业绩、SNDX因AML数据而下跌、RNA因研究数据而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CR":1,"NVAX":1,"RNA":1,"SNDX":1},"content_text":"As the third-quarter earnings season ends this week, the focus in the biotech sector is mostly on pipeline and key regulatory updates. Novavax NVAX was in focus this week as investors were disappointed with the lowered guidance.\nRecap of the Week’s Most Important Stories:\nNovavax’s Q3 Results\nNovavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per share.\nRevenues in the quarter amounted to $85 million, which beat the Zacks Consensus Estimate of $57 million. However, the top line declined 55% on a year-over-year basis.\nNovavax expects 2024 total revenues to be in the range of $650-$700 million, down from its previously issued guidance of $700-$800 million due to lower COVID-19 vaccine uptake in ex-U.S. markets.\nNovavax also announced that the FDA has lifted the clinical hold on its two pipeline programs, COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. The agency had initially placed this hold after a study participant who took the CIC shot as part of a phase II study reported nerve damage. With this hold removed, management is working with study investigators and other partners to start the phase III immunogenicity study on both vaccines as quickly as possible.\nNovavax currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nSyndax Announces Data From AML Study\nSyndax Pharmaceuticals SNDX announced positive top-line results for revumenib, an oral small-molecule menin inhibitor, from the AUGMENT-101 study. The results were announced from the relapsed or refractory (R/R) mutant NPM1 (mNPM1) acute myeloid leukemia (AML) cohort in the phase II portion of the AUGMENT-101 study of revumenib.\nThe primary endpoint was met with a complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 23%. The overall response rate was 47% in a heavily pre-treated population, including 75% with prior venetoclax exposure in the efficacy population. 17% of patients who achieved an overall response underwent hematopoietic stem cell transplant following treatment with revumenib, with three resuming revumenib therapy post-transplant. The candidate showed a favorable safety and tolerability profile, as only 5% of patients discontinued due to treatment-related adverse events.\nThe new drug application (NDA) for revumenib, an oral menin inhibitor, for the treatment of adult and pediatric relapsed or refractory (R/R) KMT2A-rearranged (KMT2Ar) acute leukemia was granted Priority Review and is being reviewed under the FDA’s Real-Time Oncology Review Program with a target action date of Dec. 26, 2024.\nSyndax plans to submit a supplemental NDA (sNDA) for treatment of R/R mNPM1 AML in the first half of 2025.\nHowever, shares declined despite the positive data readout as the efficacy data did not meet investors’ expectations.\nRNA Surges on Study Data\nAvidity Biosciences RNA announced that it is expanding its current RNA-based pipeline of rare muscle disorders to explore a new therapeutic area — precision cardiology. The company is advancing two new wholly-owned pipeline drugs, namely AOC 1086 and AOC 1072, targeting two rare genetic cardiomyopathies, PLN cardiomyopathy and PRKAG2 syndrome, respectively. Shares of the company surged on the news.\nRNA stated that both AOC 1086 and AOC 1072 have been designed to address the root causes of the genetic diseases. Based on preclinical studies conducted by Avidity, both drugs have demonstrated robust delivery of siRNA (a type of RNA molecule) against targets in the heart and reduced the number of disease-causing genes by nearly 80%.\nAvidity also shared first look at the next generation, including siRNA modifications and evolved antibody engineering. In preclinical studies, these advancements have shown a 30-fold increase in siRNA delivery to skeletal muscle and extended durability, achieving sustained target inhibition for three months.\nPerformance\nThe Nasdaq Biotechnology Index has lost 1.94% in the past five trading sessions and Moderna’s shares have lost 18.66%. In the past six months, shares of MRNA have lost 66.47%. (See the last biotech stock roundup here: Biotech Stock Roundup: FOLD Settles Patent Dispute, Updates From EDIT & More)\nImage Source: Zacks Investment Research\nWhat's Next in Biotech?\nStay tuned for more pipeline updates. \nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nNovavax, Inc. (NVAX) : Free Stock Analysis Report\nAvidity Biosciences, Inc. (RNA) : Free Stock Analysis Report\nSyndax Pharmaceuticals, Inc. (SNDX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2483331111"}